BioPharmSignal logoBioPharmSignal

Biotech News

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Nkarta (NKTX)NkartaEarnings

Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., Aug.

Related news

NKTXNkarta2026-08-10 20:24 EST

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Nkarta

Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer. NKX019 NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing. Ntrust Studies Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with...

Recent company news

NKTXNkarta2026-08-10 20:24 EST

Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights

NKTXNkarta2026-05-12 20:01 EST

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights

NKTXNkarta2026-04-15 20:01 EST

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers

NKTXNkarta2026-04-09 11:00 EST

Nkarta to Participate in Needham Virtual Healthcare Conference

NKTXNkarta2026-03-25 20:01 EST

Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights

Stock data

Close
2.66 USD
Market cap
208.2M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States